A Study of Itch in Psoriasis

Meena, Manju; Maheshwari, Kriti; Vyas, Kapil; Mittal, Asit

doi:10.4103/idoj.idoj_571_20

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Meena et al, (23) found that mild PV was detected in 132 cases while 68 cases had moderate to severe PV. In agreement with our results, itch was recorded in 172 (86%) out of 200 cases.…”

Section: Discussionmentioning

confidence: 97%

Serum Lipocalin-2 in Patients with Psoriasis Vulgaris in Relation to Itching and Psoriasis Severity

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Psoriasis vulgaris (PV) is a chronic immune-mediated inflammatory skin lesion, which affects approximately 2.5% of the populations. It is featured by erythematous plaques covered with silvery scales, in particular over the extensor surfaces, scalp, and lumbosacral region. Lipocalin-2 (LCN2) is a secreted protein belonging to the lipocalins superfamily. LCN2 stimulates neutrophils to release pro-inflammatory cytokines; IL-6, IL-8, TNF-α, and IL-1 α, via activating the 24p3R receptor on the cell surfaces. Objective: To assess the possible relation between serum lipocalin-2 levels and the degree of itch in psoriatic cases in relation to psoriasis severity. Patients and Methods: The current study was a case-control study that included 60 patients with PV and 60 healthy controls (HC) of matched age and sex. The dermatological examination included examinations of site, size, distribution of lesion, assessment of disease severity by Psoriasis Area and Severity Index score. Serum LCN2 concentrations were measured by specific ELISA kits. Results: The median Psoriasis Area and Severity Index (PASI) score among patients was 25.2 ranging from 5.7 to 56.4. All cases experienced itching. LCN2 was significantly increased among cases compared to the controls. No significant correlation was detected between LCN 2 and body mass index or PASI score. Higher levels of LCN2 were detected in patients experiencing severe itching than those with mild to moderate itching. Conclusion:The current study concluded that lipocalin-2 was markedly increased among psoriatic cases compared to psoriatic free ones. Also, lipocalin-2 seemed to have a positive correlation with psoriasis degree of itch in cases with PV but not with disease severity by measured PASI score.

show abstract

Section: Discussionmentioning

confidence: 97%

Serum Lipocalin-2 in Patients with Psoriasis Vulgaris in Relation to Itching and Psoriasis Severity

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Pruritus remains an under-recognised symptom in psoriasis, yet its prevalence and effect are substantial. Studies report that between 67% and 77% of patients with psoriasis have symptoms of pruritus which are significant and arise daily [71].…”

Section: Pruritusmentioning

confidence: 99%

Medicom Conference Report Proceedings of the 6th IFPA WPPA Conference

2021

View full text Add to dashboard Cite

The ideas and opinions expressed in this publication do not necessarily reflect those of Medicom Medical Publishers. Although great care has been taken in compiling the content of this publication, Medicom is not responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies in the original articles, or for any consequences arising from the content. Products mentioned in this report may not be covered by marketing authorisation in some countries. Product information, applicable in your country, should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. Medicom assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of PATHOGENESIS OF PSORIATIC ARTHRITIS

show abstract